Trinity Biotech PLC (TRIB)
1.802
+0.12
(+7.27%)
USD |
NASDAQ |
May 03, 16:00
1.76
-0.04
(-2.34%)
After-Hours: 20:00
Trinity Biotech Net Income (Quarterly): -5.501M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -5.501M |
| September 30, 2023 | -6.721M |
| June 30, 2023 | -5.988M |
| March 31, 2023 | -5.809M |
| December 31, 2022 | -10.08M |
| September 30, 2022 | -8.945M |
| June 30, 2022 | -9.706M |
| March 31, 2022 | -12.28M |
| December 31, 2021 | -1.265M |
| September 30, 2021 | 1.321M |
| June 30, 2021 | -0.783M |
| March 31, 2021 | 1.602M |
| December 31, 2020 | -10.02M |
| September 30, 2020 | 7.325M |
| June 30, 2020 | -1.467M |
| March 31, 2020 | -2.222M |
| December 31, 2019 | -23.32M |
| September 30, 2019 | 0.025M |
| June 30, 2019 | -5.405M |
| March 31, 2019 | -0.211M |
| December 31, 2018 | -23.96M |
| September 30, 2018 | 0.896M |
| June 30, 2018 | 0.594M |
| March 31, 2018 | 0.378M |
| December 31, 2017 | -42.86M |
| Date | Value |
|---|---|
| September 30, 2017 | 0.445M |
| June 30, 2017 | 0.902M |
| March 31, 2017 | 1.246M |
| December 31, 2016 | -100.87M |
| September 30, 2016 | -0.517M |
| June 30, 2016 | 2.104M |
| March 31, 2016 | -1.347M |
| December 31, 2015 | 2.826M |
| September 30, 2015 | 12.26M |
| June 30, 2015 | 2.694M |
| March 31, 2015 | 4.008M |
| December 31, 2014 | 4.125M |
| September 30, 2014 | 4.361M |
| June 30, 2014 | 4.315M |
| March 31, 2014 | 4.413M |
| December 31, 2013 | 4.639M |
| September 30, 2013 | -2.989M |
| June 30, 2013 | 3.828M |
| March 31, 2013 | 4.168M |
| December 31, 2012 | 4.469M |
| September 30, 2012 | 4.46M |
| June 30, 2012 | 4.302M |
| March 31, 2012 | 4.11M |
| December 31, 2011 | 4.044M |
| September 30, 2011 | 3.935M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-23.32M
Minimum
Dec 2019
7.325M
Maximum
Sep 2020
-5.223M
Average
-5.501M
Median
Dec 2023
Net Income (Quarterly) Benchmarks
| Avadel Pharmaceuticals PLC | -28.79M |
| Amarin Corp PLC | -5.781M |
| DBV Technologies SA | -11.19M |
| Adaptimmune Therapeutics PLC | -47.92M |
| Akari Therapeutics PLC | -- |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 13.43M |
| Total Expenses (Quarterly) | 16.92M |
| EPS Diluted (Quarterly) | -2.872 |
| Enterprise Value | 68.23M |
| Gross Profit Margin (Quarterly) | 34.01% |
| Profit Margin (Quarterly) | -40.97% |
| Earnings Yield | -293.4% |
| Normalized Earnings Yield | -308.22 |